Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus ENDURONYL FORTE.
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus ENDURONYL FORTE.
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE vs ENDURONYL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and further lowering blood pressure.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
1 tablet (candesartan cilexetil 16 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: 1 tablet (32 mg/25 mg) once daily.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
None Documented
None Documented
Candesartan: Terminal t1/2 ~9 hours (linear); clinically, once-daily dosing provides 24-hour antihypertensive effect. Hydrochlorothiazide: Terminal t1/2 ~6-15 hours (averaging 10 hours), prolonged in renal impairment.
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Candesartan: ~33% renal, ~67% biliary/fecal as unchanged drug and inactive metabolites. Hydrochlorothiazide: ≥95% renal as unchanged drug.
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic + Rauwolfia Alkaloid